Castle Biosciences (CSTL) Receivables - Net (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Receivables - Net data on file, last reported at $42.3 million in Q1 2026.

• Quarterly Receivables - Net fell 25.0% year-over-year to $42.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.3 million (down 25.0% YoY) and the FY2025 annual result came in at $43.4 million, down 15.3% from the prior year.
• Receivables - Net declined to $42.3 million in Q1 2026 per CSTL's latest filing, from $43.4 million in the prior quarter.
• The five-year high for Receivables - Net was $56.4 million in Q1 2025, with the low at $19.9 million in Q1 2022.
• Average Receivables - Net over 5 years is $38.7 million, with a median of $42.3 million recorded in 2026.
• Year-over-year, Receivables - Net surged 63.15% in 2023 and declined 25.0% in 2026.
• Castle Biosciences' Receivables - Net stood at $23.5 million in 2022, then jumped by 63.15% to $38.3 million in 2023, then jumped by 33.72% to $51.2 million in 2024, then fell by 15.3% to $43.4 million in 2025, then fell by 2.58% to $42.3 million in 2026.
• Business Quant data shows CSTL's Receivables - Net at $42.3 million in Q1 2026, $43.4 million in Q4 2025, and $49.5 million in Q3 2025.